Consegna Pharma Inc.
Pittsburgh, PA
- UEI
- NU7SAKDR52N8
- CAGE
- 806W6
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2403 Sidney St #285, Pittsburgh, PA 15203, USA
- Website
- consegnapharma.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Phase II - base period | ACC Aberdeen Proving Ground | $1,100,000 | |
| Army sbir phase I | ACC Aberdeen Proving Ground | $167,421 |
Grant awards
Similar vendors
About the company
Consegna Pharma Inc. is a specialty pharmaceutical company that develops long-acting injectable medications. Through federal contract and grant awards, Consegna provides pharmaceutical research and development services focused on reformulating drugs to create improved treatments.
Consegna has been awarded federal contracts from the Department of the Army to conduct pharmaceutical research related to chemical and biological defense. This includes a $1,099,999 Phase II SBIR contract to research and develop a long-duration opioid overdose antagonist, as well as a $167,421 Army SBIR Phase I contract for additional pharmaceutical research. Both contracts were set aside for small businesses.
Consegna has also received federal grants from the National Institute on Drug Abuse for pharmaceutical research and development projects related to treatments for substance abuse disorders and prevention of opioid overdoses. This includes a $1,330,781 project grant to advance development of a 12-24 hour naloxone formulation to prevent opioid overdose renarcotization. Another $326,500 project focuses on development of a 28-day injectable ketamine formulation to improve substance abuse disorder treatment. A prior $305,204 project grant funded development of a treatment to prevent opioid overdose renarcotization from synthetic opioids.
Quick answers
Is Consegna Pharma Inc. registered in SAM.gov?
Yes. Consegna Pharma Inc.'s SAM.gov registration is active through February 2, 2027.
What is Consegna Pharma Inc.'s CAGE code?
Consegna Pharma Inc.'s CAGE code is 806W6, and its Unique Entity ID (UEI) is NU7SAKDR52N8.
What is Consegna Pharma Inc.'s most recent federal award?
Consegna Pharma Inc.'s most recent federal grant award is IND-enabling development of a long-duration antagonist to treat opioid overdose (R44DA050386), from National Institute on Drug Abuse (NIH), on September 15, 2023.
On GovTribe
See Consegna Pharma Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors